NO20024270L - Vedvarende frigivelsesranolazinformuleringer - Google Patents

Vedvarende frigivelsesranolazinformuleringer

Info

Publication number
NO20024270L
NO20024270L NO20024270A NO20024270A NO20024270L NO 20024270 L NO20024270 L NO 20024270L NO 20024270 A NO20024270 A NO 20024270A NO 20024270 A NO20024270 A NO 20024270A NO 20024270 L NO20024270 L NO 20024270L
Authority
NO
Norway
Prior art keywords
sustained release
release ranolazine
ranolazine formulations
formulations
sustained
Prior art date
Application number
NO20024270A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024270D0 (no
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24074628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024270(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20024270D0 publication Critical patent/NO20024270D0/no
Publication of NO20024270L publication Critical patent/NO20024270L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20024270A 2000-03-08 2002-09-06 Vedvarende frigivelsesranolazinformuleringer NO20024270L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/520,932 US6479496B1 (en) 1998-09-10 2000-03-08 Methods for treating angina with ranolazine
PCT/US2001/007287 WO2001066093A2 (en) 2000-03-08 2001-03-07 Sustained release ranolazine formulations

Publications (2)

Publication Number Publication Date
NO20024270D0 NO20024270D0 (no) 2002-09-06
NO20024270L true NO20024270L (no) 2002-11-06

Family

ID=24074628

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024270A NO20024270L (no) 2000-03-08 2002-09-06 Vedvarende frigivelsesranolazinformuleringer

Country Status (17)

Country Link
US (1) US6479496B1 (sl)
EP (1) EP1263439A2 (sl)
JP (2) JP4108980B2 (sl)
CN (1) CN1323664C (sl)
AU (3) AU4009201A (sl)
BR (1) BR0109091A (sl)
CA (1) CA2402222C (sl)
CZ (1) CZ20022996A3 (sl)
HK (1) HK1058003A1 (sl)
HU (1) HUP0204409A3 (sl)
IL (1) IL151575A0 (sl)
MX (1) MXPA02008654A (sl)
NO (1) NO20024270L (sl)
NZ (1) NZ521292A (sl)
PL (1) PL357273A1 (sl)
RU (1) RU2002126615A (sl)
WO (1) WO2001066093A2 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
EP1505977B1 (en) 2002-05-21 2014-09-10 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
AU2004264939A1 (en) 2003-08-11 2005-02-24 Middlebrook Pharmaceuticals, Inc. Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2535780A1 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSED DELIVERY
EP1841411A2 (en) * 2005-01-06 2007-10-10 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CN100455288C (zh) * 2006-06-26 2009-01-28 哈药集团制药总厂 一种盐酸雷诺嗪制剂配方
US20080031949A1 (en) * 2006-07-24 2008-02-07 Cima Labs Inc. High dose orally dissolvable/disintegrable lyophilized dosage form
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008101008A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
KR20100038322A (ko) * 2007-05-31 2010-04-14 씨브이 쎄러퓨틱스, 인코포레이티드 당뇨병 치료 방법
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
CA2690379A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
EA201070914A1 (ru) * 2008-02-06 2011-04-29 Гайлид Сайэнсиз, Инк. Применение ранолазина для лечения боли
CA2761771A1 (en) * 2009-05-14 2010-11-18 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
NO3175985T3 (sl) 2011-07-01 2018-04-28
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)
JP7500379B2 (ja) 2020-09-30 2024-06-17 文化シヤッター株式会社 開閉装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
EP0407780B1 (en) * 1989-06-23 1996-09-11 Syntex (U.S.A.) Inc. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
JP2000336032A (ja) * 1999-05-26 2000-12-05 Kissei Pharmaceut Co Ltd ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物

Also Published As

Publication number Publication date
IL151575A0 (en) 2003-04-10
HK1058003A1 (en) 2004-04-30
CZ20022996A3 (cs) 2003-09-17
HUP0204409A2 (en) 2003-05-28
CA2402222A1 (en) 2001-09-13
NO20024270D0 (no) 2002-09-06
CA2402222C (en) 2009-11-03
RU2002126615A (ru) 2004-03-20
CN1323664C (zh) 2007-07-04
PL357273A1 (en) 2004-07-26
MXPA02008654A (es) 2004-09-06
AU2008212005A1 (en) 2008-09-25
AU2001240092B8 (en) 2004-12-02
WO2001066093A2 (en) 2001-09-13
WO2001066093A3 (en) 2002-03-14
JP2008069159A (ja) 2008-03-27
JP2003525896A (ja) 2003-09-02
EP1263439A2 (en) 2002-12-11
US6479496B1 (en) 2002-11-12
BR0109091A (pt) 2005-02-15
NZ521292A (en) 2008-07-31
AU2001240092B2 (en) 2004-10-14
CN1443069A (zh) 2003-09-17
AU4009201A (en) 2001-09-17
HUP0204409A3 (en) 2005-04-28
JP4108980B2 (ja) 2008-06-25

Similar Documents

Publication Publication Date Title
NO20024270L (no) Vedvarende frigivelsesranolazinformuleringer
DK1096937T3 (da) Ranolazinformuleringer med langvarig frigivelse
DK1317177T3 (da) Desinficerende formuleringer
NO20031483D0 (no) Vaksine
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
NO20024172D0 (no) Vaksine
DE60128599D1 (de) Arbeitsgerät
ATA2932001A (de) Schneefräse
ATE262530T1 (de) Indolochinazolinone
DE60033666D1 (de) Verstärker
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
ATE268116T1 (de) Mesotrion-formulierungen
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
AR027931A1 (es) Antitranspirantes
DE10052925B4 (de) Schaukelbett
ATE476423T1 (de) Benzoylpyridazine
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
ATE284887T1 (de) Thienopyrrolidinone
DE10054120B4 (de) Aufsparrendämmelement

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application